1067613-13-1

Basic information

• Product Name: 3-fluoro-4-(1-methyl-1H-pyrazol-5-yl)benzoic acid
• Synonyms: 3-fluoro-4-(1-methyl-1H-pyrazol-5-yl)benzoic acid
• CAS NO: 1067613-13-1
• Molecular Weight: 220.203
• Mol File: 1067613-13-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 3-fluoro-4-(1-methyl-1H-pyrazol-5-yl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-fluoro-4-(1-methyl-1H-pyrazol-5-yl)benzoic acid(1067613-13-1)
• EPA Substance Registry System: 3-fluoro-4-(1-methyl-1H-pyrazol-5-yl)benzoic acid(1067613-13-1)

Safety Data

• Hazardous Substances Data: 1067613-13-1(Hazardous Substances Data)

Upstream product

• 849758-12-9 methyl 4-bromo-3-fluorobenzoate 
• 1044851-76-4 5-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-1-methyl-1H-pyrazole 
• 153556-42-4 4-bromo-3-fluorobenzoic acid 

Downstream Products

• 1067613-55-1 4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-N-((1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-3-fluorobenzamide 
• 1067613-46-0 1,1-dimethylethyl [2-({[4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-3-fluorophenyl]carbonyl}amino)-3-phenylpropyl]carbamate 
• 1067613-44-8 4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-3-fluorobenzoic acid 
• 1067613-16-4 N-((1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-3-fluoro-4-(1-methyl-1H-pyrazol-5-yl)benzamide 

Relevant articles and documents

Discovery of N-((3 S,4 S)-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1 H-pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity

Rash is one of the primary dose-limiting toxicities of Akt (protein kinase B) inhibitors in clinical trials. Here, we demonstrate the inhibition of Akt2 isozyme may be a driver for keratinocyte apoptosis, which promotes us to search for new selective Akt inhibitors with an improved cutaneous safety property. According to our previous research, compound 2 is selected for further optimization for overcoming the disadvantages of compound 1, including high Akt2 inhibition and high toxicity against HaCaT keratinocytes. The dihedral angle-based design and molecular dynamics simulation lead to the identification of Hu7691 (B5) that achieves a 24-fold selectivity between Akt1 and Akt2. Hu7691 exhibits low activity in inducing HaCaT apoptosis, promising kinase selectivity, and excellent anticancer cell proliferation potencies. Based on the superior results of safety property, pharmacokinetic profile, and in vivo efficacy, the National Medical Products Administration (NMPA) approved the investigational new drug (IND) application of Hu7691.